July 25, 2024
Anggraeni Endah Kusumaningrum, Ardianto Sucinta
In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research shows the potential of psychedelic substances such as psilocybin, LSD, and MDMA to treat disorders such as major depression, post-traumatic stress disorder (PTSD), and substance addiction. However, the clinical use of psychedelic substances remains...
Sleep Medicine
July 1, 2024
Andreas S Lappas, Eleni Glarou, Zoi A Polyzopoulou et al.
13 citations
Sleep disturbances are an important symptom dimension of post-traumatic-stress-disorder (PTSD). There is no meta-analytic evidence examining the effects of all types of pharmacotherapy on sleep outcomes among patients with PTSD. Medline/Embase/PsychInfo/CENTRAL/clinicaltrials.gov/ICTRP, reference lists of published reviews and all included studies were searched for Randomised Controlled Trials...
Current Opinion in Psychiatry
July 1, 2024
Stephen N. Xenakis, Scott Shannon
5 citations
The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divide limits effective resolution of a practice delivery quandary: is this primarily a pharmacological or psychotherapeutic intervention? Lykos (formerly MAPS) has submitted its new drug application (NDA) request to the FDA for...
Sexual medicine reviews
June 26, 2024
Maggie N Mott, Nicholas E Goeders
3 citations
Recreational psychostimulants have been associated with increased sexual activity or changes in sexual function in women, but every drug in this class has not shown consistent sexual effects in scientific studies. Further, some studies in female animal models may recapitulate the effects observed in humans, while others produce conflicting results. Overall, though, published studies on the...
Journal of Psychedelic Studies
June 21, 2024
Caroline Griffin, Alec Knight
3 citations
AbstractBackground and aimsPsychedelics show promise for treatment of mental health conditions (MHCs). But there is relatively little research on indigenous psychedelics conducted in the Global South (GS). Much research is carried out in the Global North, where there are different cultural perceptions of mental health and psychedelics. Therefore, this paper appraises research on psychedelics...
medRxiv
June 20, 2024
Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar
preprint
Abstract Background Hallucinogens attract research as alternatives to the commonly used medications to treat major depressive and anxiety disorders. Aims Assess hallucinogens’ efficacy for managing depressive and anxiety symptoms and evaluate their safety profiles. Method In five databases, we searched for randomized controlled trials of hallucinogens targeting depressive and anxiety symptoms....
Journal of Clinical Investigation
June 17, 2024
Alejandro Torrado Pacheco, Bita Moghaddam
3 citations
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiatric disorders. All clinical data collected so far with regard to psilocybin or MDMA, which have reported positive outcomes for treating depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders, have involved...
Science
June 14, 2024
Kai Kupferschmidt
3 citations
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.
Psychiatria
June 5, 2024
Anna Stankiewicz, Jan Szewczyk, Julia Truszkowska et al.
1 citation
Drug therapies for many psychiatric conditions do not meet patients’ expectations. New agents are being sought to treat depression and anxiety disorders, among others. Scientific interest in psychoactive substances has increased over the past few decades. Recent studies provide evidence that psychedelics may find use in the treatment of a range of mental disorders. This paper describes new...
June 3, 2024
Terence Han Wei Ching
preprint
Background: Systemic diversification of psychedelic research is needed, in light of interest in psychedelics for healing among Black, Indigenous, and Peoples of Color (BIPOC) and queer communities. Doing so also contributes to an inclusive evidence base, ethically meeting the anticipated demand for psychedelic treatments post-approval. Aims: Here, a primer for culturally attuned psychedelic...